Back to search results

Imaging Studies in Corticobasal Syndrome

This observational study is looking into corticobasal syndrome (CBS), a brain disorder affecting movement and thinking. Researchers want to understand if inflammation and damage to the brain's white matter are related in CBS. They will use special PET scans, including C-11 ER176 to look for inflammation, C-11 PiB to look for amyloid protein, and AV1451 Tau to look for Tau protein. They will also collect blood samples. The main goal is to see how C-11 ER176 PET imaging shows neuroinflammation and white matter health in people with CBS. You may be able to join if you are 18 or older and meet the criteria for possible or probable CBS. The study is currently unclear on its recruitment status.

Study design
This is an observational study with a planned enrollment of 80 participants. It is not specified if this is a randomized or blinded study.
What's involved
The primary endpoint will be measured at approximately 4-5 years into study visits. The specific number of visits or procedures is not detailed.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint will be evaluated at approximately 4-5 years into study visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07000851

Imaging Studies in Corticobasal Syndrome

Recruiting
Not specifiedAges 18+Observational
Jennifer Whitwell
~80 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:C-11 ER176 RadiotracerC-11 PiBAV1451 Tau

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The investigators will use C-11 ER176 PET imaging to evaluate neuroinflammation and white matter integrity in CBS
Measured over approximately 4-5 years into study visits

Conditions

Cortico Basal Degeneration
Corticobasal Syndrome
Corticobasal Syndrome(CBS)
Corticobasal Degeneration
Corticobasal Degeneration (CBD)
Corticobasal Syndrome (CBS)

Explore related trials

Corticobasal DegenerationCorticobasal syndrome

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Jennifer Whitwell, Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Megan J Meyer, M.B.A.
[email protected]
507-293-1164
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older
Meet possible or probable CBS criteria

Exclusion

Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)
Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome
Subjects will be excluded if they have a mutation in the progranulin gene
Subjects will excluded if they have received anti-Aβ therapy
Women who are pregnant will be excluded
Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)
Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning

What this trial measures

  • The investigators will use C-11 ER176 PET imaging to evaluate neuroinflammation and white matter integrity in CBSapproximately 4-5 years into study visits

    Measure whether regional patterns of ER176-PET uptake and white matter microstructure abnormalities using NODDI differ between CBS-4R, CBS-AD, Amn-AD, and HC.